Hainan Shuangcheng Pharmaceut - Asset Resilience Ratio
Hainan Shuangcheng Pharmaceut (002693) has an Asset Resilience Ratio of 0.69% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 002693 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Hainan Shuangcheng Pharmaceut's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 002693 total asset value.
Liquid Assets Composition Over Time
This chart breaks down Hainan Shuangcheng Pharmaceut's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Hainan Shuangcheng Pharmaceut long-term investment allocation to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥5.61 Million | 0.69% |
| Total Liquid Assets | CN¥5.61 Million | 0.69% |
Asset Resilience Insights
- Limited Liquidity: Hainan Shuangcheng Pharmaceut maintains only 0.69% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hainan Shuangcheng Pharmaceut Industry Peers by Asset Resilience Ratio
Compare Hainan Shuangcheng Pharmaceut's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for Hainan Shuangcheng Pharmaceut (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Hainan Shuangcheng Pharmaceut.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.01% | CN¥46.43K ≈ $6.79K |
CN¥825.78 Million ≈ $120.84 Million |
+0.01pp |
| 2024-12-31 | 0.00% | CN¥2.83K ≈ $413.53 |
CN¥783.87 Million ≈ $114.70 Million |
-3.55pp |
| 2023-12-31 | 3.55% | CN¥28.52 Million ≈ $4.17 Million |
CN¥803.25 Million ≈ $117.54 Million |
-11.14pp |
| 2022-12-31 | 14.69% | CN¥133.81 Million ≈ $19.58 Million |
CN¥911.02 Million ≈ $133.31 Million |
+8.20pp |
| 2021-12-31 | 6.48% | CN¥55.40 Million ≈ $8.11 Million |
CN¥854.56 Million ≈ $125.05 Million |
-3.90pp |
| 2020-12-31 | 10.38% | CN¥94.25 Million ≈ $13.79 Million |
CN¥907.68 Million ≈ $132.82 Million |
+4.83pp |
| 2019-12-31 | 5.55% | CN¥52.80 Million ≈ $7.73 Million |
CN¥950.98 Million ≈ $139.16 Million |
-6.94pp |
| 2018-12-31 | 12.50% | CN¥139.98 Million ≈ $20.48 Million |
CN¥1.12 Billion ≈ $163.93 Million |
+1.80pp |
| 2017-12-31 | 10.69% | CN¥147.25 Million ≈ $21.55 Million |
CN¥1.38 Billion ≈ $201.52 Million |
+10.26pp |
| 2016-12-31 | 0.43% | CN¥5.00 Million ≈ $731.66K |
CN¥1.17 Billion ≈ $170.55 Million |
+0.21pp |
| 2015-12-31 | 0.22% | CN¥3.37 Million ≈ $493.14K |
CN¥1.55 Billion ≈ $226.84 Million |
-40.06pp |
| 2014-12-31 | 40.27% | CN¥380.00 Million ≈ $55.61 Million |
CN¥943.54 Million ≈ $138.07 Million |
-- |
About Hainan Shuangcheng Pharmaceut
Hainan Shuangcheng Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical injections, solid preparations, and raw materials in China and internationally. The company offers products for oncology and immune, alimentary canal, heart and cerebral, and vessels and metabolism. It also provides Bivalirudin, Epitifibatide, and Thymalfaxin for injection; Pre… Read more